Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Neuro-Oncology AdvancesOpen Access

H3K27M- and BRAF V600E-Altered Gliomas and Glioneuronal Tumors—Clinico-Pathologic and Radiologic Perspective in a Cohort Treated with Targeted Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

CCCarolyn G ChenVRVanessa RamehTRTom Rosenberg

Discussion

Loading...

Member takes

Overview

Observational analysis reveals distinct outcomes linked to histologic and molecular features in BRAF V600E gliomas, suggesting targeted therapy benefits.

Key Points

  • Patients with low-grade glioma had better outcomes, averaging 38 months survival, while high-grade cases showed limited survival similar to classic H3K27M gliomas.
  • Eight patients treated with BRAF/MEK inhibitors were analyzed for histologic variability, and clinical outcomes highlighted the impact of tumor morphology.
  • Molecular features were reviewed alongside histology, revealing variants associating with prognosis and the need for targeted therapeutic approaches in gliomas.
  • Patients underwent varying surgical interventions; maximal safe resections correlated with improved outcomes, particularly in low-grade glioma-like tumors.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68c195649b7b07f3a0619764https://doi.org/10.1093/noajnl/vdaf197
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An Emerging Pediatric CNS Tumor: Imaging Evaluation of <i>H3K27M</i> and <i>BRAF V600E</i> Comutated Midline Tumors2025
  2. 2PATH-77. Clinical and molecular predictors of survival and treatment response in AYA/adults with BRAF-V600 mutant high-grade glioma2025
  3. 3Abstract 155: Clinico-radiological and histomolecular analyses identify of a new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered2024
  4. 4ID #395 Clinical presentation and outcomes across different BRAF alterations in pediatric low-grade gliomas2026
  5. 5Abstract 5137: BRAF mutations in primary central nervous system tumors2024 · 2 citations